SEC Company Response from INTERLEUKIN GENETICS INC (CIK 0001037649) — Jul 19, 2005
INTERLEUKIN GENETICS INC (CIK 0001037649)
Date: July 19, 2005 · CIK: 0001037649 · Accession: 0001104659-05-032847
AI Filing Summary & Sentiment
File numbers found in text: 000-23413
Referenced dates: July 7, 2005
Letter
Interleukin Genetics, Inc.
135 Beaver Street, Waltham MA
July 18, 2005
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Todd Sherman
Re:
Interleukin Genetics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2004
File No: 000-23413
Ladies and Gentlemen:
In response to the letter dated July 7, 2005 from Jim B. Rosenberg of the Staff, Interleukin Genetics, Inc. (the “Company”) hereby acknowledges the following:
• The Company is responsible for the adequacy and accuracy of the disclosure in its filings;
• Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and
• The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Interleukin Genetics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Interleukin Genetics, Inc. 135 Beaver Street, Waltham MA 02254 July 18, 2005 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Todd Sherman Re: Interleukin Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2004 File No: 000-23413 Ladies and Gentlemen: In response to the letter dated July 7, 2005 from Jim B. Rosenberg of the Staff, Interleukin Genetics, Inc. (the “Company”) hereby acknowledges the following: • The Company is responsible for the adequacy and accuracy of the disclosure in its filings; • Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and • The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Interleukin Genetics, Inc. By: /s/ Fenel M. Eloi Fenel M. Eloi Chief Financial Officer, Chief Operating Officer and Secretary.